Globeflex Capital L P Takes $1.49 Million Position in iRadimed Corporation $IRMD

Globeflex Capital L P acquired a new position in iRadimed Corporation (NASDAQ:IRMD) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 15,546 shares of the medical equipment provider’s stock, valued at approximately $1,486,000.

Several other hedge funds have also recently bought and sold shares of the company. Quarry LP bought a new stake in iRadimed during the 3rd quarter valued at $40,000. Farther Finance Advisors LLC grew its stake in shares of iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 397 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares in the last quarter. CWM LLC increased its holdings in shares of iRadimed by 19.5% during the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after purchasing an additional 107 shares during the period. Finally, Global Retirement Partners LLC acquired a new position in shares of iRadimed during the second quarter valued at $84,000. 92.34% of the stock is currently owned by institutional investors.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the completion of the sale, the chief executive officer directly owned 2,162,500 shares of the company’s stock, valued at $195,922,500. This represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 34.60% of the stock is owned by corporate insiders.

iRadimed Stock Performance

Shares of NASDAQ:IRMD opened at $87.18 on Tuesday. The firm has a 50 day simple moving average of $93.31 and a 200 day simple moving average of $94.38. iRadimed Corporation has a 52 week low of $67.84 and a 52 week high of $107.90. The company has a market cap of $1.12 billion, a PE ratio of 48.70 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.02. The company had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, equities analysts predict that iRadimed Corporation will post 1.98 earnings per share for the current year.

iRadimed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 28th. Shareholders of record on Friday, August 14th will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, August 14th. iRadimed’s payout ratio is 44.69%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on IRMD shares. Wall Street Zen downgraded shares of iRadimed from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings cut shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $120.00.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.